Clinical Studies

     

Scientific studies prove the efficacy
of uninterrupted insulin pump therapy.

 

For more than a decade, researchers have examined the safety and efficacy of insulin pump therapy (also known as continuous subcutaneous insulin infusion (CSII) therapy). When possible we offer reprints of journal articles related to these studies for your convenience.

 

Please note, you must have Adobe® Acrobat Reader® on your computer to view many of these articles. If you do not have this software, you can download a free copy.

 

Siphon Effects of Continuous Subcutaneous Insulin Infusion Pump Delivery Performance
Journal of Diabetes Science and Technology, 2010

Researchers tested three conventional pumps (with tubing) along with the OmniPod to quantify the siphon effects in the tubing with continuous subcutaneous insulin infusion (CSII) during basal and bolus insulin delivery. This study demonstrated that changing the position of a conventional CSII pump in relation to the insulin infusion site results in significant changes in insulin delivery especially during low bolus rates.
Copyright © 2010 Diabetes Technology Society

From Journal of Diabetes Science and Technology, Vol. 4, 2010; 98-103
Reprinted with permission from Diabetes Technology Society.

 

Clinical Experience with a Tubing-Free Insulin Pump System
Infusystems USA, 2009

A retrospective, 1 year study of clinical experience with the OmniPod System in patients with both Type 1 and Type 2 diabetes and who had previously been on either MDI or pump therapy with a conventional pump. The study showed that the OmniPod system demonstrated improvements in glycemic control with patients previously on MDI.
Copyright © 2009 Infusystems USA

From Infusystems USA, Vol. 6, 2009; 25-27
Reprinted with permission from Infusystems USA.

 

Quantifying the Impact of a Short-Interval Interruption of Insulin-Pump Infusion Sets on Glycemic Excursions
Diabetes Care, 2008

A prospective, open-label study measured the impact of short-term insulin infusion set disconnects on glucose levels. It shows that even short-term interruption of insulin delivery can cause blood glucose levels to rise and remain elevated for hours post-interruption.
Copyright © 2008 American Diabetes Association
From Diabetes Care®, Vol. 31, 2008; 238-239
Reprinted with permission from The American Diabetes Association.

 

Insulin Pump Therapy: A meta-analysis
Diabetes Care, 2003
Examining the metabolic and psychosocial impact of insulin pump therapy, this study concluded that insulin pumps improve glycemic control as compared with other therapies.
Copyright © 2003 American Diabetes Association
From Diabetes Care®, Vol. 26, 2003; 1079-1087
Reprinted with permission from The American Diabetes Association.

 

Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Regimens Using Insulin Lispro in Type 1 Diabetic Patients on Intensified Treatment
Diabetes Care, 2000
A randomized study compared the efficacy of two treatment regimes: continuous subcutaneous insulin infusion (insulin pump therapy) and multiple daily injections (MDI). Subjects using insulin pumps achieved much better glycemic control using less insulin than subjects using MDI.
Copyright © 2000 American Diabetes Association
From Diabetes Care®, Vol. 23, 2000; 1232-1235
Reprinted with permission from The American Diabetes Association.

 

Reduction in Severe Hypoglycemia With Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes
Diabetes Care, 1996
This study compared the incidence of severe hypoglycemia in patients who switched to continuous subcutaneous insulin infusion (CSII) from multiple daily injections (MDI). It concluded that CSII therapy produced a “marked and sustained reduction” in hypoglycemia, due to the reproducible and flexible insulin delivery.
Copyright © 1996 American Diabetes Association
From Diabetes Care®, Vol. 19, 1996; 324-327
Reprinted with permission from The American Diabetes Association.

 

*These clinical studies were performed with the OmniPod System PDM model UST200.

 

 

A | A | A









©2013 Insulet Corporation. All rights reserved. Content in MyOmniPod.com is intended for residents of the United States (and Puerto Rico) only. As a result, the site may contain information about products or uses of those products, and promotional offers that are not approved in other countries. If you are a resident of a country other than United States, please visit the Internation section of the site to obtain appropriate information for your country of residence.

Learn about the next-generation OmniPod at
MyOmniPodTraining.com